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Introduction
Overactive bladder (OAB) is a common condition,
comprising a symptom complex that includes uri-
nary urgency, frequency and in one-third of
patients, urgency-associated incontinence (1). The
ﬁrst-line pharmacological treatment for OAB is
with antimuscarinics (2), which aim to reduce the
frequency and intensity of involuntary contractions
of the bladder detrusor muscle primarily via block-
ade of muscarinic M3 receptors (3,4). As with
many medications, there is a delicate balance
between the efﬁcacy and the tolerability⁄safety pro-
ﬁle of antimuscarinics. A thorough discussion of
the physiological and pharmacological basis for the
efﬁcacy and the side effects of these medications
was recently published (5). Attention has focused
recently on the potential impact of these medica-
tions on the central nervous system (CNS). An
important factor for consideration is whether the
choice of antimuscarinic therapy can inﬂuence
CNS outcomes, and evidence is accumulating for
differences between antimuscarinic drugs in their
potential to adversely affect memory and other
aspects of cognitive function.
However, several other factors may also contri-
bute to the CNS risk including patient age, con-
comitant conditions and associated treatments.
These may affect CNS function individually or in a
complex interplay when combined. The prevalence
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SUMMARY
Background: Antimuscarinic agents used in the treatment of overactive bladder
(OAB) differ in their potential to impair cognitive function. It is hypothesised that
low brain concentrations and relatively low selectivity for the M1 muscarinic recep-
tor may reduce the potential for adverse central nervous system (CNS) effects with
darifenacin, compared with other antimuscarinics, particularly oxybutynin. Meth-
ods: Cognitive function studies evaluating darifenacin, oxybutynin, tolterodine, soli-
fenacin and⁄or trospium were identiﬁed from publications databases (Medline,
Biosis and Embase) and congress abstracts. Preclinical studies and randomised con-
trolled trials in adults were reviewed. Results: Five randomised, double-blind, mul-
tiple-dose studies of cognitive function were identiﬁed. Oxybutynin was consistently
associated with cognitive deﬁcit (four studies), whereas darifenacin did not impair
cognition (three studies). These ﬁndings were supported by data from sleep⁄atten-
tion and EEG studies. Tolterodine data were limited to one small study with each
formulation. For solifenacin and trospium, there were no human studies evaluating
memory, the cognitive function most vulnerable to CNS anticholinergics. Conclu-
sions: There is compelling evidence of cognitive impairment with oxybutynin,
whereas darifenacin stands out by demonstrating no impairment of memory or
other cognitive functions in three randomised, controlled trials. This may be attrib-
uted to the differences in physicochemical properties, efﬂux mechanisms and rela-
tive M1 muscarinic receptor sparing. The risk of CNS impairment is of particular
concern for vulnerable populations such as the elderly (a substantial proportion of
the OAB population), and CNS-compromised neurogenic bladder patients such as
those with multiple sclerosis or Parkinson’s disease.
Review Criteria
• Electronic publication databases (Medline, Biosis
and Embase) were searched using the terms
‘muscarinic antagonists’ plus ‘mental
processes ⁄drug effects’ or ‘cognition’.
• Preclinical studies and clinical trials in adults
were evaluated, focusing on the following
agents: darifenacin, oxybutynin, solifenacin,
tolterodine and trospium.
• Abstracts on these agents from key
urology⁄ incontinence congresses (International
Consultation on Incontinence; International
Continence Society; American Urological
Association; European Association of Urology)
between 2002 and 2007 were also examined.
Message for the Clinic
• Antimuscarinics used in the treatment of
overactive bladder differ in their potential to
affect cognitive function.
• In particular, treatment with agents that block
M1 receptors in the brain are known to cause
cognitive impairment.
• Darifenacin and tolterodine stand out as having
been shown to not cause impairment of memory
or other cognitive functions in randomised clinical
trials.
Linked Comment: Janos et al. Int J Clin Pract 2008; 62: 1641–2.
doi: 10.1111/j.1742-1241.2008.01849.x
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therefore many patients receiving OAB antimuscari-
nic therapy are likely to have multiple comorbidi-
ties and to be taking several concomitant
medications.
Thus, advancing age is itself associated with decline
in cognitive function and increasing permeability of
the blood–brain barrier, which can increase a patient’s
susceptibility to the CNS effects of medications with
anticholinergic effects, in the absence of other con-
tributing factors (8). The presence of neurological
conditions such as multiple sclerosis, Parkinson’s
disease or stroke per se also increases the risk for
developing cognitive dysfunction and is associated
with increased permeability of the blood–brain barrier
(9). As antimuscarinics are routinely prescribed for
patients whose OAB symptoms arise from such neu-
rological conditions, patients receiving antimuscarinic
therapy may have comorbidities that may predispose
them to further CNS effects from antimuscarinic
therapy. In addition, medications given concomi-
tantly for a variety of unrelated comorbid conditions
may have ‘hidden’ anticholinergic effects, which add
to the total anticholinergic burden on the patient
and, consequently, impaired cognitive function.
Indeed, multiple studies have reported a high preva-
lence of elevated anticholinergic load in elderly
patients, and the cognitive consequences of this
burden [e.g. (10–12)].
Because a substantial number of patients may be
vulnerable to the adverse CNS effects of antimuscari-
nic therapy, efforts to minimise further risk are
important. One factor for consideration is whether
the choice of antimuscarinic therapy can inﬂuence
CNS outcomes, because evidence is accumulating for
the differences between antimuscarinic drugs in their
potential to adversely affect cognition.
This paper discusses the pharmacological basis for
these differences, and reviews the preclinical and
clinical evidence for CNS effects of commonly used
antimuscarinic agents (i.e. darifenacin, oxybutynin,
tolterodine, solifenacin and trospium). These clinical
data include studies of drug effects on cognition,
sleep and EEG.
Pharmacological basis for differential
cognitive effects of antimuscarinic
drugs
Antimuscarinic agents interact with receptors
throughout the body, including the M3 receptors of
the bladder detrusor muscle, which are thought to be
the primary target for antimuscarinic therapy in
OAB (3,4). In the CNS, all ﬁve of the known musca-
rinic receptor subtypes are expressed (5). Although
the role of each subtype in the brain has not yet been
fully elucidated, interactions with M1,M 2 and M4
muscarinic receptor subtypes have each been impli-
cated in cognitive impairment (5,8,13–15). However,
the muscarinic M1 receptor subtype, in particular, is
thought to play a crucial role in modulating cogni-
tive function (5,8,13). Evidence for a dominant role
for the M1 receptor includes the severe impairment
of working memory seen in M1 knockout mice
(mutants deﬁcient in M1 receptors) and in animals
administered intra-hippocampal injections of the M1
receptor antagonist pirenzepine (16–18), as well as
the potential for muscarinic M1 agonist therapy to
improve cognitive function in patients with dementia
(19). By contrast, studies with M3 knockout mice
have shown no impact on cognition or behaviour
(20). Therefore, antimuscarinic therapy that is most
selective for the M3 subtype combined with relative
M1 sparing properties would be expected to have the
lowest potential for adverse effects on cognition.
However, for an agent to exert a CNS effect, it
must ﬁrst reach the appropriate receptors in sufﬁ-
cient concentration. Thus, the extent to which an an-
timuscarinic agent can disrupt CNS function will
depend upon several factors including (i) the ability
of the drug to enter the brain, (ii) accumula-
tion⁄retention within the brain in sufﬁcient concen-
trations and (iii) interaction with muscarinic
receptors within the brain, particularly M1 receptors.
CNS penetration
Overactive bladder antimuscarinic agents differ with
respect to their ability to penetrate the blood–brain
barrier passively, and the extent to which they are
actively transported across the blood–brain-barrier
by transporter proteins such as P-glycoprotein and
the multidrug-resistance-associated proteins (MRPs;
e.g. MRP1–9). Passive penetration is the greatest for
non-polar molecules of small molecular size and high
lipophilicity (i.e. limited solubility in alcohol) (8,13).
Oxybutynin, a relatively small (357 kDa), highly lipo-
philic molecule can readily cross the blood–brain
barrier, whereas other antimuscarinics are consider-
ably larger (e.g. tolterodine 475.6 kDa, solifenacin
480.6 kDa and darifenacin 507.5 kDa), a factor
which would hinder CNS penetration (13). Similarly,
trospium, a (428.0 kDa), hydrophilic quaternary
ammonium antimuscarinic compound, can be
expected to show low penetrative ability under nor-
mal conditions.
However, all antimuscarinic agents have the poten-
tial to cross the blood–brain barrier under certain
circumstances, because the integrity of the barrier
can become disrupted in the presence of a range of
conditions such as diabetes, Alzheimer’s disease,
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ease and advancing age (8,13,21–23). As reviewed
elsewhere (8,13), the mechanisms involved in this
increased permeability are diverse, and may include
epithelial shrinkage and capillary dilatation in the
brain. For example, trauma to the brain has been
shown to induce the expression of junctional adhe-
sion molecule, which appears to lead to the break-
down of blood–brain barrier (24). Under these
conditions, the potential for drug penetration into
the CNS is increased, and the ability of the drug to
remain in the brain and interact with speciﬁc musca-
rinic receptors becomes critical.
CNS accumulation
There are few preclinical publications evaluating the
concentrations of antimuscarinic drugs in the brain.
One study with oxybutynin evaluated CNS penetra-
tion in terms of muscarinic receptor occupancy in
conscious rhesus monkeys, using positron emission
tomography (25). After single oral (p.o.) doses of
oxybutynin 0.1 or 0.3 mg⁄kg, peak plasma concen-
trations of oxybutynin and its active metabolite
(N-desethyl-oxybutynin) were reached at 30 min
(7.9 ± 7.1 and 29.1 ± 36.4 ng⁄ml at 0.1 mg⁄kg, and
21.9 ± 10.9 and 63.1 ± 53.6 ng⁄ml at 0.3 mg⁄kg
respectively). At 1 h after the 0.1 and 0.3 mg⁄kg
doses, muscarinic receptor occupancy in each brain
region evaluated (frontal, temporal and occipital cor-
tices, cingulate gyrus, caudate, amygdala, putamen,
hippocampus, thalamus and cerebellum) was esti-
mated to be about 40% and 60% respectively. These
levels decreased at 4 h postdose, in line with plasma
concentrations.
By contrast, two publications of tissue distribution
in rodents administered
14C-labelled tolterodine or
14C-darifenacin indicated relatively low CNS penetra-
tion and accumulation of these agents (26,27). In
mice administered
14C-tolterodine as single (4 or
12 mg⁄kg), or as repeated p.o. doses (12 mg⁄kg⁄day
for 7 days), brain concentrations at 2 h postdose
were 0.07, 0.45 and 0.99 lg equivalents⁄g, compared
with plasma concentrations of 0.39, 1.08 and 1.47 lg
equivalents⁄ml, respectively, i.e. brain concentrations
ranged from 18% to 67% of those achieved in
plasma at the same time points (26). Similarly, in
rats given
14C-darifenacin 4 mg⁄kg intravenously
(i.v.), brain concentrations were 66% and 29% of
blood concentrations at 5 min and 1 h postdose
(0.37 vs. 0.56 lg equivalents⁄g at 5 min, and 0.13 vs.
0.44 lg equivalents⁄g at 1 h) respectively (27). How-
ever, a second study in the same publication reported
somewhat lower CNS penetration following p.o.
administration of 10 mg⁄kg
14C-darifenacin in rats,
with cervical spinal ﬂuid concentrations in pooled
samples obtained at 1 and 4 h postdose approxi-
mately 10% of those in plasma dialysate (14.5 vs.
139.3 lg equivalents⁄ml).
As drug accumulation in the brain is dependent
not only on passive penetration through the blood–
brain barrier, but also on persistence within the
brain, it is of interest that there are speciﬁc efﬂux
mechanisms. Darifenacin transport is mediated by
P-glycoprotein (28), and that of trospium chloride
by one of the MRPs (29), while there are no known
active mechanisms for other OAB antimuscarinics.
These active transport mechanisms reduce the poten-
tial for the drug to accumulate and remain within
the CNS and may contribute to the observation of
very low penetration of
14C-darifenacin into the
brain relative to other tissues (27).
While CNS concentrations of an antimuscarinic
agent are important, an additional consideration is
the additive CNS impact of an elevated drug burden
associated with the use of multiple medications with
anticholinergic activity (11). This is a particular con-
cern for the older patient, as this is the population
most subject to polypharmacy, often including the
use of inappropriate medications with anticholinergic
effects (30). In older patients, particular care is war-
ranted to limit the anticholinergic load that may
contribute to cognitive impairment.
CNS muscarinic receptor binding
Following drug penetration and accumulation within
the brain, the ability of an agent to block critical M1
receptor sites is a key factor contributing to drug-
related cognitive dysfunction. Several studies have
compared the OAB antimuscarinics to determine
their relative in vitro binding selectivity for different
muscarinic receptor subtypes (31–40). These studies
have shown that darifenacin demonstrates consis-
tently high relative selectivity for the M3 receptor
subtype (which is presumed to be the primary target
for OAB therapy) over the other receptor subtypes.
Darifenacin demonstrated a selectivity ratio of 9.3 : 1
for the M3 receptor over the M1 subtype in a com-
parative study by Napier and Gupta (33), and 16 : 1
in a more recent competitive binding study (35). By
contrast, other antimuscarinic agents were consis-
tently found to be relatively non-selective for M3
receptors, with ratios of binding for M3 over M1
receptors ranging from 0.5 (i.e. a twofold greater
binding afﬁnity for M1 than M3 receptors) to 2.5
across all studies (31–40).
Overall, these ﬁndings suggest that the potential
for negative cognitive effects among all currently
available OAB drugs is likely to be the highest for
oxybutynin, which demonstrates a high propensity
for CNS penetration and accumulation coupled with
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subtype. By contrast, for darifenacin, a drug with
low CNS perfusion (arising from limited penetration
and active efﬂux from the brain) and which has rela-
tively low afﬁnity for muscarinic M1 receptors, the
potential for adverse CNS effects would be expected
to be much lower. In order to conﬁrm the clinical
relevance of these differences in penetration, accu-
mulation and selectivity proﬁles, data from speciﬁc
cognitive function studies and sleep⁄EEG studies
with OAB antimuscarinics are reviewed below, focus-
ing in particular on studies with oxybutynin and dar-
ifenacin.
Cognitive effects of OAB
antimuscarinics in animal studies
Several papers have reported the behavioural effects
in rodents of antimuscarinic drugs currently used for
the treatment of OAB (41–44). Three studies evalu-
ated the effects of oxybutynin in rats, using propiver-
ine as a comparator and⁄or scopolamine as a
positive control, and in each study, oxybutynin
administration was associated with signiﬁcant
impairment of memory. In the most recent study,
tolterodine had no effect on memory in mice under-
going a passive-avoidance test at 1 or 3 mg⁄kg p.o.
(doses resulting in concentrations estimated be up to
six times the therapeutic levels in man), in contrast
to the memory impairment (decreased latency)
observed with scopolamine 3 mg⁄kg (44). Darifena-
cin was evaluated only in one recent study and, in
contrast to oxybutynin, was not associated with cog-
nitive deﬁcits (43). In this study, antimuscarinic
agents (oxybutynin, darifenacin, tolterodine, solifena-
cin, propiverine or scopolamine) were administered
i.v. to rats 10 min before an initial passive-avoidance
task (acquisition) and latency time was measured
when the task was repeated 24 h later (retention).
Administration of oxybutynin (0.1–1 mg⁄kg), propi-
verine (1–10 mg⁄kg) or scopolamine (0.1–1 mg⁄kg)
signiﬁcantly impaired memory retention, seen as
dose-dependent reductions in latency. Tolterodine
had no effect at lower doses (0.3 or 0.1 mg⁄kg), but
showed a trend for impaired learning at the highest
dose (1 mg⁄kg; p = 0.054 for the reduction in
latency), although this represents 100· the doses of
tolterodine required to affect bladder contractions
(assessed as inhibition of carbachol-induced increase
in intravesical pressure). By contrast, darifenacin
(0.1–1 mg⁄kg) and solifenacin (0.3–3 mg⁄kg) did
not affect retention even at the highest doses, which
represented 102· and 130· the doses required to
inhibit carbachol-induced bladder contraction
respectively.
The extent to which these animal models translate
into clinical differences in CNS effects between com-
monly used OAB antimuscarinics is examined further
by a review of published data from controlled clinical
trials.
Cognitive effects of OAB
antimuscarinics in double-blind clinical
studies
Several prospective, randomised, double-blind, clini-
cal studies have evaluated the effects of antimuscari-
nic drugs on cognitive function at steady state (i.e.
after at least 7 days of dosing), as summarised in
Table 1 (45–49). Oxybutynin was evaluated in four
studies involving a total of 315 subjects, and was
consistently associated with deterioration in cognitive
function. By contrast, darifenacin administration
compared with placebo, in three studies involving a
total of 302 subjects, resulted in no signiﬁcant effect
on learning or memory in healthy adults (45–47).
All three darifenacin studies assessed cognition
using a battery of computerised tests, and evaluated
both doses approved for the treatment of OAB
(7.5⁄15 mg once daily). Two of the studies involved a
large number of older subjects (n = 129 and 150,
‡ 60 years of age). In a study conducted with youn-
ger adults (n = 27, age 19–44 years), each treatment
(darifenacin 7.5 and 15 mg, dicyclomine, and pla-
cebo) was administered for 1 week (45). The two
clinical doses of darifenacin were compared with the
M1-selective muscarinic antagonist dicyclomine (used
as a positive control). Although darifenacin had no
effect on memory or other cognitive functions, dicy-
clomine resulted in signiﬁcant impairment of cogni-
tive function, which was observed on ﬁve of the 12
cognitive function variables assessed (45). In the sec-
ond study, older subjects (n = 129, age 65–84 years)
received either darifenacin (7.5 mg and 15 mg⁄day)
or placebo (46). Test results showed that performance
on cognitive testing was comparable for the two
clinical doses of darifenacin and placebo.
In a third study, the effects of darifenacin on cog-
nitive function were compared with those of both
oxybutynin extended release (ER) and placebo
(n = 150, age 60–83 years) (47). Dose escalation was
conducted according to the US prescribing informa-
tion of both drugs.
At both doses (7.5 and 15 mg), darifenacin had no
signiﬁcant effects on memory compared with pla-
cebo. By contrast, oxybutynin ER resulted in deterio-
ration in memory over time, with signiﬁcant
differences observed from week 1 (at 10 mg⁄day) for
secondary measures and from week 2 (at 15 mg⁄day)
for the primary outcome measure (delayed recall on
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References Study design, tests and patients Treatments Key outcomes
Multiple-dose studies
Kay et al. (47) Randomised, double-blind, parallel
group, multicentre study (3 weeks
of treatment)
Computerised CFT (10 tests) performed
at baseline and weeks 1, 2 and 3
150 healthy men and women
(60–83 years)
Darifenacin (n = 49): 7.5 mg⁄day
(weeks 1 and 2) then 15 mg⁄day
(week 3)
Oxybutynin ER (n = 50): 10 mg⁄day
(week 1),
15 mg⁄day (week 2), 20 mg⁄day
(week 3)
Placebo (n = 51): weeks 1–3
Delayed recall (NFAT) at week 3 not
signiﬁcantly different between
darifenacin and placebo
Delayed recall (NFAT) at week 3
signiﬁcantly impaired with oxybutynin
(p < 0.05 vs. placebo or vs. darifenacin)
comparable to 16 years of brain ageing
No between-group differences in
self-rated memory (i.e. subjects unaware
of memory deterioration)
Kay and Wesnes (45) Randomised, double-blind, 4-way
cross-over study (7-day treatment
and 7-day washout periods)
Computerised CFT (12 variables)
and EEG recordings performed
at baseline and day 7 of each treatment
23 healthy men (19–44 years)
Darifenacin 7.5 mg⁄day
Darifenacin 15 mg⁄day
Dicyclomine (positive control:
M1 selective
antimuscarinic) 20 mg qid
Placebo
No signiﬁcant effect on CFT with either
dose of darifenacin and no clinically
relevant effects on EEG
Impaired performance on 5⁄12
variables at 2 h postdose with dicyclomine
accompanied by EEG slowing
Lipton et al. (46) Randomised, double-blind, 3-period
crossover study (14-day treatment
and 7-day washout periods),
each subject receiving 3 of 5 treatments
Computerised CFT (5 tests) at baseline
and week 2 of each treatment period
129 healthy men and women
(65–84 years)
Darifenacin 3.75 mg⁄day (n = 65)
Darifenacin 7.5 mg⁄day (n = 70)
Darifenacin 15 mg⁄day (n = 61)
Darifenacin IR* 5 mg tid (n = 65)
Placebo (n = 66)
Darifenacin not signiﬁcantly different
from placebo for primary end-points
of CFT (MSS, SCRT, WRS) at any dose
No changes in self-rated alertness or
contentment with darifenacin vs. placebo
Kay et al. (47) Randomised, double-blind, crossover study
(2 · 3-week treatment periods
with 7 days of washout)
Computerised CFT performed at baseline
and 3 weeks
22 healthy men and women
(mean age 63 years)
Tolterodine ER 4 mg⁄day
(weeks 1–3, with sham titration)
Oxybutynin ER: 10 mg⁄day
(week 1), 15 mg⁄day (week 2),
20 mg⁄day (week 3)
No signiﬁcant change in delayed recall
(NFAT) or other outcome measures from
baseline to week 3 of tolterodine treatment
Delayed recall (NFAT) at week 3 signiﬁcantly
impaired with oxybutynin vs. baseline
comparable to 20 years of ageing
Delayed recall performance signiﬁcantly
worse with oxybutynin ER than
tolterodine ER at week 3 but not at
earlier time points
No awareness of changes in memory at
any time point
Nagels et al. (49) Randomised, double-blind, crossover study
(2 · 8-week treatment periods)
CFT included PASAT and ADAS-Cog tests;
MACFIMS and MMSE were also assessed
14 patients with MS (ages not speciﬁed)
Oxybutynin IR 2.5 mg tid
Tolterodine IR 2 mg bid
Tolterodine was associated with a trend
to better performance on PASAT than
oxybutynin
ADAS-Cog and MMSE did not differ
between treatment periods
Single-dose studies
Katz et al. (50) Randomised, double-blind,
placebo-controlled cross-over
study (single doses with 1-week washout)
Combination of pencil and paper, interview
and computerised CFT (15 tests lasting
1 h), starting 90 min postdose
12 healthy men and women (75–76 years)
Oxybutynin HCl 5m g
Oxybutynin HCl 10 mg
Diphenhydramine HCl (positive
control: antihistamine with known
anticholinergic and cognitive effects)
50 mg
Placebo
Oxybutynin at both doses caused
signiﬁcant decrements on 7⁄15
cognitive measures
Diphenhydramine caused signiﬁcant
decrements on 5⁄15 cognitive measures
Effects of oxybutynin remained signiﬁcant
after Bonferroni correction
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the signiﬁcant decline in memory performance,
which is equivalent to that of 16 years of cognitive
ageing, participants receiving oxybutynin ER were
not aware of any change in their memory.
Cognitive function studies with other OAB agents
in adults are limited, and each involves relatively
small numbers of subjects (Table 1). Two small
studies, which are available only as published
abstracts, have compared the CNS effects of toltero-
dine and oxybutynin at steady state. The more
recent of these was a double-blind, 3-week, cross-
over study (n = 22) in older adults (mean age
63 years) comparing tolterodine ER (4 mg⁄day)
with oxybutynin ER (10–20 mg⁄day). The study
showed that oxybutynin ER 20 mg⁄day impaired
cognitive performance relative to baseline, whereas
no decline was seen with tolterodine ER (48). The
other study compared the cognitive effects of oxy-
butynin immediate release (IR) (2.5 mg three times
daily) with tolterodine IR (2 mg twice daily) in 14
patients with multiple sclerosis who also had com-
plaints of OAB and cognitive difﬁculties (49). The
results of this cross-over study indicated a trend
towards better performance during treatment with
tolterodine compared with oxybutynin.
Three further studies evaluated the effects of single
doses of IR oxybutynin in small numbers of subjects
(Table 1) (50–52). The ﬁrst of these compared the
acute effects of IR oxybutynin (5 or 10 mg), diphen-
hydramine (50 mg) and placebo on cognitive func-
tion in older adults (‡ 65 years) (50). The effect of
oxybutynin appeared to be at least as great as that
of diphenhydramine, an antihistamine with marked
anticholinergic activity that served as the positive
control for the study. The remaining two studies
were primarily evaluations of sleep effects (see below)
in healthy young (n = 24, 22–36 years) and older
volunteers (n = 24, 51–65 years) but also assessed
some cognitive parameters (51,52). Both studies
compared the effects of single doses of trospium
(45 mg) and oxybutynin IR (15 mg) or tolterodine
IR (4 mg). Reaction time, assessed using the Zahlen–
Verbindungs Test (a number combination test) and
attention⁄concentration (the d2 test) evaluated at 1 h
postdose showed no signiﬁcant differences between
these treatments and placebo. However, the clinical
relevance of these ﬁndings is limited by the study
design, in which cognitive effects were evaluated at a
single time point following administration of a single
dose and did not include an assessment of memory.
Effects of OAB antimuscarinics
in sleep and EEG studies
Several studies have evaluated the effects of OAB an-
timuscarinics on brain biomarkers including sleep
and⁄or EEG. Although the link between such effects
and cognitive function is unclear, these studies can
be used as indicators of the potential effect of a drug
on brain function. Overall, the results support the
study ﬁndings reviewed above suggesting differential
effects of OAB antimuscarinics on cognitive function.
Sleep parameters
Two randomised, double-blind, cross-over studies
compared the effects of single doses of oxybutynin
IR (15 mg), tolterodine IR (4 mg), trospium
Table 1 (continued)
References Study design, tests and patients Treatments Key outcomes
Diefenbach et al. (52) Randomised, double-blind, placebo-controlled,
cross-over study (single doses with 8-day washout)
Sleep study with additional assessment of reaction
time (ZVT) and attention (d2 test) 1 h postdose
24 healthy men and women (51–65 years)
Trospium 45 mg
Oxybutynin IR 15 mg
Tolterodine IR 4 mg
Placebo
No signiﬁcant differences between any
drug and placebo in reaction time on ZVT,
or number of items completed⁄mistakes or
target items missed in d2 test
Diefenbach et al. (51) Randomised, double-blind, placebo-controlled,
cross-over study (single doses with 8-day washout)
Sleep study with additional assessment of reaction
time (ZVT) and attention (d2 test) 1 h postdose
24 healthy men and women (22–36 years)
Trospium 45 mg
Oxybutynin IR 15 mg
Tolterodine IR 4 mg
Placebo
No signiﬁcant differences between any drug
and placebo in reaction time on ZVT, or
number of items completed⁄mistakes or
target items missed in d2 test
*Non-marketed formulation. Administered as liquids diluted to 100 ml in fruit juice. ADAS-Cog, Alzheimer’s disease assessment scale, cognitive subscale; bid, twice
daily; CFT, cognitive function tests; ER, extended release; HCl, hydrochloride salt; IR, immediate release; MACFIMS, Minimal Assessment of Cognitive Function in
Multiple Sclerosis; MMSE, Mini-Mental State Examination; MS, multiple sclerosis; MSS, memory scanning sensitivity; NFAT, name–face association test; PASAT,
paced auditory serial addition test; qid, four times daily; SCRT, speed of choice reaction time; tid, three times daily; WRS, word recognition sensitivity; ZVT, Zahlen–
Verbindungs test.
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36 years) or older (51–65 years) subjects (51,52). In
both studies, oxybutynin resulted in reductions in
rapid eye movement (REM) sleep as a proportion of
total sleep time (p < 0.05 vs. trospium in younger
subjects; p = 0.002 vs. placebo in older subjects),
accompanied by increases in REM latency (p = 0.03
vs. placebo, p = 0.001 vs. trospium, p = 0.045 vs.
tolterodine in younger subjects; not signiﬁcant in
older subjects). The proportion of REM sleep was
also reduced by tolterodine vs. placebo in older sub-
jects (p = 0.0002), but was not signiﬁcantly altered
in younger subjects. Further evaluation in a pooled
analysis of these two studies indicated that toltero-
dine also reduced the proportion of REM sleep in
subjects who were classiﬁed as poor metabolisers or
intermediate metabolisers based on CYP2D6 status
(53). No studies have been published evaluating sleep
parameters during darifenacin administration.
Quantitative EEG studies
Two quantitative EEG studies in healthy volunteers
compared the effects of oxybutynin and trospium, the
more recent of which also evaluated tolterodine
(54,55). In the earlier open-label study, 12 healthy
men (26 ± 4 years) received single doses of oxybuty-
nin (20 mg) or trospium chloride either i.v. (1.2 mg)
or orally (45 mg), at intervals of at least 6 days. Oxy-
butynin signiﬁcantly altered quantitative EEG parame-
ters during eyes-open, eyes-closed and reaction-time
test periods, whereas i.v. trospium led to a marginal
decrease only during the eyes-closed period, and oral
trospium resulted in no signiﬁcant changes (54). In
the more recent study, 64 healthy men (18–35 years)
received trospium (15 mg · 3 doses), oxybutynin
(5 mg · 3 doses) or tolterodine (2 mg · 2 doses) each
for 1 day (doses given at 5-h intervals), in a single-
blind, cross-over design (55), and EEG was recorded
at baseline and up to 4 h after each dose. Trospium or
tolterodine administration did not produce any
important changes in quantitative EEG parameters
compared with placebo, whereas oxybutynin caused
signiﬁcant power reductions in four frequency bands.
The EEG effects of darifenacin have also been
reported (without quantitative analysis) in one of the
cognitive function studies discussed earlier (45).
Placebo or darifenacin administration (7.5 or
15 mg⁄day for 7 days) resulted in no clinically rele-
vant effect on EEG, whereas the positive control
(dicyclomine) resulted in EEG slowing.
Summary and conclusions
The risk of cognitive impairment during anti-
muscarinic therapy for OAB is an important
concern, particularly for those with comorbid
conditions that may impair CNS function and which
are frequently associated with concomitant neuro-
genic bladder. Also included are persons taking mul-
tiple medications, with anticholinergic activity, which
contribute to the anticholinergic load. It is notewor-
thy, that drug-induced deterioration in memory and
the effects on other cognitive processes are often
unnoticed and unreported by the patient.
Evaluation of the pharmacological mechanisms
that could contribute to drug-induced effects on cog-
nition suggests that antimuscarinic OAB agents differ
in their ability to penetrate the blood–brain barrier,
accumulate and interact with the M1 receptor in the
brain. Amongst the antimuscarinic agents evaluated,
darifenacin displays the greatest relative selectivity
for the M3 receptor over the M1 subtype, whereas all
other agents were relatively non-selective.
In this review, ﬁve randomised, controlled trials
investigating cognitive function under OAB anti-
muscarinics administration in steady-state conditions
have been reviewed (45–49). Substantial differences
exist between the individual agents. In particular, oxy-
butynin has consistently been shown to cause deterio-
ration in memory, the parameter considered to be the
most sensitive to anticholinergic effects. In contrast, no
such impairment was seen with darifenacin in the three
studies which investigated this agent. Similarly, no
cognitive decline was seen with tolterodine in two mul-
tiple-dose studies (48,49), although the ﬁndings need
to be interpreted with caution because of the small
number of subjects and the absence of a placebo con-
trol group. In addition, these two studies used different
formulations of tolterodine (i.e. immediate and ER).
Impairment of CNS functioning was also seen in
studies evaluating the effects of single doses of oxy-
butynin on cognition (50–52), sleep, and EEG (51–
56), whereas trospium, was found to be free of
impairment of attention, sleep and EEG parameters.
Unfortunately, there are no known studies investigat-
ing the effect of trospium on memory.
Overall, this review indicates that a considerable
body of preclinical and clinical data has accumulated
to suggest that oxybutynin can cause cognitive impair-
ment, which is further supported by the ﬁndings from
sleep studies and quantitative EEG analyses. Indeed,
the strength of evidence of an increased risk of CNS
adverse events with oxybutynin has been recognised
by the US Food and Drug Administration, resulting
in new precautions in the labels for oxybutynin-
containing products. Under the heading, Central
Nervous System Effects, the new labels state that
‘patients should be monitored for signs of anticholin-
ergic CNS effects, particularly in the ﬁrst few months
after beginning treatment or increasing the dose’ (57).
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evaluated, darifenacin was found to have the largest
body of evidence demonstrating no impairment of
memory or other cognitive functions in younger and
older adults. This evidence is fully consistent with
the darifenacin proﬁle, which is characterised by its
low CNS penetration and accumulation, in addition
to its relative M1 receptor sparing properties.
In conclusion, the ﬁndings from this review indi-
cate that appropriate selection of OAB medications is
important in order to minimise the risk of CNS
effects and enable long-term treatment for OAB with
conﬁdence in the safety of the therapy. Further long-
term evaluation and postmarketing studies are
awaited to conﬁrm this safety proﬁle in clinical prac-
tice.
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